Skip to content
CDC

Antimicrobial Resistance

Multidrug-resistant Pseudomonas aeruginosa

% Resistant in 2024

8.2% Resistant

Number of Resistant Isolates of the Total Number of Isolates Tested In 2024

632 Resistant

/ 7,678 Tested

% Resistant by Patient Age in 2024

Pediatric:
9.7% Resistant
Adult:
8.2% Resistant

Pathogen Profile

Multidrug-resistant Pseudomonas aeruginosa

Pseudomonas aeruginosa is a common cause of healthcare-associated infections including pneumonia, bloodstream infections, urinary tract infections, and surgical site infections. Some P. aeruginosa are becoming more resistant to even antibiotics of last resort, and are described as multidrug-resistant.

Current Threat Report

Threat LevelSerious

Estimated Cases32,600

Estimated Deaths2,700

Healthcare Costs (USD)$767 M

Source: COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2024

Years Included
2011 - 2024
Resources

Geographic Locations

Antimicrobial resistance varies by location, driven by a number of factors, including antibiotic use and infection control practices in individual healthcare facilities, the underlying health and age of the patient population, and regional spread from nearby locations.

Percent Multidrug resistance Among Pseudomonas aeruginosa by State Map

This map shows the variation in % multidrug resistance among Pseudomonas aeruginosa causing all event types in 2024.

Percent Multidrug resistance Among Pseudomonas aeruginosa by State

Percent Multidrug resistance Among by State
Locationvalue
Alabama12.5
AlaskaInsufficient Data
Arizona6.1
Arkansas6.2
California8.4
Colorado1.1
Connecticut1.5
Delaware8
District of Columbia12.2
Florida7
Georgia11.1
Hawaii14.3
Idaho3.8
Illinois9.1
Indiana6.7
Iowa7.8
Kansas2.6
Kentucky7.1
Louisiana5
Maine6.7
Maryland12.1
Massachusetts11
Michigan9.5
Minnesota10.1
Mississippi10.8
Missouri8.4
MontanaInsufficient Data
Nebraska2.2
Nevada9.2
New Hampshire10
New Jersey9.4
New Mexico6.8
New York12.3
North Carolina5.7
North DakotaInsufficient Data
Ohio9.7
Oklahoma6.8
Oregon6.6
Pennsylvania6.7
Puerto Rico31
Rhode Island9.1
South Carolina6.4
South Dakota6.9
Tennessee8
Texas8.3
Utah10
VermontInsufficient Data
Virginia1.8
Washington7.1
West Virginia0
Wisconsin1.5
WyomingInsufficient Data

Percent Multidrug resistance Among Pseudomonas aeruginosa by State List

Geography

Geography
statevalue
United States8.2%
Alabama12.5%
AlaskaNo Data
Arizona6.1%
Arkansas6.2%
California8.4%
Colorado1.1%
Connecticut1.5%
Delaware8.0%
District of Columbia12.2%

Changes Over Time in Multidrug resistance Among Pseudomonas aeruginosa

This graph displays percent antimicrobial resistance from 2011 to 2024 for all event types. Blank areas of the chart represent 0% resistance, indicating that zero resistant pathogens were reported for the selected year, phenotype, and HAI type. “Insufficient data” indicates that less than 20 pathogens were isolated and tested for resistance.

Due to definition changes, caution should be used when reviewing this phenotype over time.

Changes Over Time in Multidrug resistance Among Pseudomonas aeruginosa
Year% Resistant
201115.7
201213.3
201314.9
201413.6
201513.3
201612.7
201710.5
20189
20197.9
20207.7
20218.9
20228.3
20237.7
20248.2

Healthcare Facility Type

The setting or type of healthcare facility can influence the types of procedures and prevention measures that are related to healthcare-associated infections and antimicrobial resistance.

Multidrug resistance Among Pseudomonas aeruginosa by Hospital Type

This graph displays percent antimicrobial resistance by hospital type in 2024.

Percent resistant Among Pseudomonas aeruginosa by Hospital Type

Percent resistant Among Pseudomonas aeruginosa by Hospital Type
Hospital Type% Resistant
General Acute Care Hospitals7.8
Long Term Acute Care Hospitals18.4
Inpatient Rehabilitation Facilities4.5

Footnotes

  • HAIs include Catheter-associated Urinary Tract Infections (CAUTI), Central Line-associated Bloodstream Infections (CLABSI), and Surgical Site Infections (SSI).
  • CI (Confidence Interval) - The national, regional, and state-level data included in Antimicrobial Resistance information are displayed with 95% confidence intervals around the percent resistance, which were calculated using a mid-P exact test and are an indication of precision.
  • Map legends are classified using the Jenks Natural Breaks method.
  • The definition for this phenotype underwent changes in 2021. For more information, refer to the AR&PSP Phenotype Definitions.